23,166 Shares in Edwards Lifesciences Corporation $EW Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC invested $1.68 million in Edwards Lifesciences Corporation by acquiring 23,166 shares in the first quarter, according to their recent SEC filing.
• Recent insider trading includes VP Donald E. Bobo, Jr. selling 2,570 shares and insider Larry L. Wood selling 8,950 shares, both resulting in slight decreases in their ownership stakes.
• The stock received multiple upgrades from analysts, with a current average rating of "Moderate Buy" and a target price of $85.90.

Jump Financial LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,166 shares of the medical research company's stock, valued at approximately $1,679,000.

Other large investors have also bought and sold shares of the company. Nuveen LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth about $330,881,000. Jennison Associates LLC lifted its holdings in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after acquiring an additional 2,576,383 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Edwards Lifesciences in the fourth quarter valued at about $92,631,000. Northern Trust Corp grew its position in Edwards Lifesciences by 21.8% during the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock worth $481,582,000 after acquiring an additional 1,165,845 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $84,787,000. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock worth $1,698,844 in the last three months. Corporate insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EW. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Morgan Stanley lifted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Stifel Nicolaus upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.25 on Monday, hitting $81.48. 2,743,784 shares of the company were exchanged, compared to its average volume of 3,802,425. The firm has a market capitalization of $47.84 billion, a P/E ratio of 11.72, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The stock's 50 day moving average price is $78.31 and its 200 day moving average price is $75.01. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.